A fungal infection that resists every drug a doctor throws at it. A bacterial outbreak on a wheat field that shrugs off standard treatments. These are the scenarios that antimicrobial resistance makes more common every year, and a team at Flinders University in Australia believes a new sulfur-based material could help change the equation.
In a study published in April 2026 in the journal Chemical Science, researchers describe a water-soluble polymer built from chains of sulfur atoms, known as a poly(trisulfide), that destroyed dangerous fungi and bacteria in laboratory tests without harming human or plant cells. If that selectivity holds up beyond the lab, the compound could fill a gap that has frustrated physicians and farmers alike: the lack of antimicrobials that kill pathogens without poisoning everything around them.
Why selectivity matters
Most antimicrobial agents work like a sledgehammer. They damage pathogen cells, but they also damage the patient’s tissue or the crop they are meant to protect. That toxicity trade-off limits dosing, narrows treatment windows, and sometimes forces clinicians to choose between fighting an infection and protecting an organ.
The Flinders polymer appears to sidestep that problem. According to the university’s announcement, the compound disrupts microbial cell walls through a chemical mechanism that mammalian and plant cells can tolerate. Microbial membranes differ structurally from human cell membranes, and the polymer exploits those differences to deliver targeted damage.
The peer-reviewed paper, identified by DOI 10.1039/D5SC09816E, details testing against pathogens that the World Health Organization classifies as priority threats. A preprint version of the work had circulated earlier on ChemRxiv, giving outside scientists a head start on evaluating the experimental data before formal publication.
The resistance crisis in numbers
The discovery arrives against a grim backdrop. A landmark 2022 analysis published in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for roughly 1.27 million deaths worldwide in 2019 and played a role in nearly five million more. The WHO’s antimicrobial resistance fact sheet warns that the problem is accelerating, driven by overuse of antibiotics in both healthcare and agriculture.
Fungi present a parallel threat that receives less public attention. WHO published its first-ever fungal priority pathogens list in 2022, flagging species like Candida auris and Aspergillus fumigatus as critical concerns. Antifungal drug development has lagged far behind antibacterial research for decades, leaving clinicians with a thin and aging toolkit.
A compound that works against both bacteria and fungi, without collateral damage to the host, would address two fronts of the resistance crisis simultaneously. That is the promise the Flinders team is putting forward.
From hospital wards to farm fields
The researchers have framed the polymer as a dual-use material, one that could treat infections in patients and protect crops from microbial disease. The Flinders University release names international collaborators involved in testing and describes intended applications spanning clinical infection control and agricultural protection.
That ambition is worth noting, but also worth qualifying. Agricultural pathogens operate in soil, water, and open air, environments far less controlled than a hospital lab. A polymer that performs well in a petri dish may behave differently when sprayed on a rice paddy or mixed into irrigation water. Temperature, UV exposure, soil chemistry, and interactions with beneficial microbes all introduce variables that laboratory conditions do not capture.
No field trial data for agricultural use has been released. The dual-use framing remains an aspiration stated in promotional materials rather than a demonstrated outcome.
What the polymer still has to prove
Every promising lab discovery faces the same gauntlet: animal studies, human safety trials, regulatory review, and eventually, real-world deployment. The Flinders polymer has cleared only the first hurdle. No clinical trial records or formal toxicology studies beyond the laboratory data in the Chemical Science paper have been publicly disclosed as of April 2026.
The gap between killing a pathogen on a glass slide and doing so safely inside a living patient is enormous. Compounds that look selective in vitro sometimes trigger immune responses, accumulate in organs, or break down into toxic byproducts once they enter a biological system. Only controlled animal and human testing can answer those questions.
Independent replication is another critical milestone. The selectivity findings come from a single research group. Until other laboratories reproduce the results with their own samples and protocols, the scientific community will treat the claims as preliminary.
It is also worth noting that no global health authority has endorsed or assessed the polymer. The WHO data cited in connection with the discovery provides context for why new antimicrobials are needed, not a stamp of approval for this particular compound.
Where the science goes next
For researchers tracking the antimicrobial pipeline, three developments will signal whether the polymer moves from curiosity to candidate. First, publication of animal model data showing the compound works in a living organism without unacceptable side effects. Second, independent replication of the selectivity results by at least one outside laboratory. Third, engagement from a regulatory body, whether that is Australia’s Therapeutic Goods Administration, the U.S. Food and Drug Administration, or another agency, indicating that formal review is underway.
None of those steps has happened yet. The polymer sits squarely in the early discovery phase: chemically interesting, biologically promising, and years away from a pharmacy shelf or a farmer’s spray tank. But in a world where resistant infections kill more than a million people annually and the antifungal cupboard is nearly bare, even an early-stage breakthrough that targets pathogens without harming healthy cells deserves close attention. The Flinders team has given the field something concrete to test. Now the testing begins.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
